Amplifying Virus like Particles (AVLP)
- Detailed Technology Description
- None
- *Abstract
-
Application
This technology is a Parainfluenza Virus 5 (PIV-5)-based amplifying virus like particle (AVLP) that can be used to safely induce the expression of proteins of interest for a variety of animal and human health applications, including vaccination, gene therapy, and cancer therapy.
Technology Summary
Many types of modified viruses have been used for therapeutic applications; however, each type of virus has a limited use for which it is best suited due to drawbacks such as: safety concerns, limited gene expression levels, and limited capacity to express DNA. There exists a need for a more flexible and versatile approach to deliver genes of interest to desirable locations.
Researchers at the University of Georgia have recently developed a new AVLP platform system based on a PIV-5 virus that safely delivers expressible heterologous nucleotides of interest to a target cell without producing viral progeny. This platform contains a variety of features including a "suicide" protein which allows killing of AVLP-contain cells at will as well as the ability to add a selection marker. Preliminary studies have shown that this platform works for vaccine, gene therapy, and regenerative medicine applications.
ProblemsAddressed
- Safety: AVLPs can amplify foreign genes within targetcells but are non-infectious and cannot produce progeny.
- Efficacy: When used as a vaccine, AVLPs generaterobust immune responses
- Versatility: AVLPs can be applied in virtually anymammalian cell type and can also be engineered to target specific cell types
- Cost-Effectiveness: AVLP-based vaccines are inexpensiveto produce
(Additional details in the attached PDF)
- Country/Region
- USA
